TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9256141

Group type: EXPERIMENTAL
Intervention: Dolasetron (2.4 mg/kg I.V. prechemotherapy, followed by 200 mg oral once daily for 6 days)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Ondansetron (32 mg I.V. or 8 mg orally twice daily)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg I.V. followed by 8 mg oral once daily for 6 days) added to dolasetron
Number of subjects: 696

Group type: COMPARATOR
Intervention: Dexamethasone (8 mg I.V. followed by 8 mg oral once daily for 6 days) added to ondansetron
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Dexamethasone added to both dolasetron and ondansetron
Number of subjects: 696

Group type: COMPARATOR
Intervention: Dolasetron and ondansetron
Number of subjects: 696
Study: 8289411

Group type: EXPERIMENTAL
Intervention: Enteral nutrition support via percutaneous endoscopic gastrostomy with a casein and soy-based polymeric formula blended with a modular protein (group A)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Total parenteral nutrition through a subclavian venous catheter (group B)
Number of subjects: 48
Study: 2941052

Group type: EXPERIMENTAL
Intervention: Diane (high dose cyproterone acetate with ethinyloestradiol)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Minovlar (standard oestrogen and progestagen contraceptive pills)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High dose CPA
Number of subjects: 90
Study: 31629643

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study: 28943018

Group type: EXPERIMENTAL
Intervention: Lipomimetic drop (Systane® Balance)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non‐lipid containing drop (Systane® Ultra)
Number of subjects: 30
Study: 27358493

Group type: EXPERIMENTAL
Intervention: 8 weeks of controlled cycling and walking training at 80% individual Vo2 peak
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TGF-β1 as inhibitor of mitochondrial regulators and insulin signaling
Number of subjects: 20
Study: 24934642

Group type: EXPERIMENTAL
Intervention: Multicomponent dietary intervention
Number of subjects: 0
Study: 22313192

Group type: EXPERIMENTAL
Intervention: Internet-delivered behavioral intervention supplemented with video coaching
Number of subjects: 45
Study: 20534872

Group type: EXPERIMENTAL
Intervention: Integrative health coaching
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study: 18451243

Group type: EXPERIMENTAL
Intervention: 3-weekly docetaxel
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: weekly docetaxel
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: mitoxantrone
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: PSA response
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: pain response
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: QoL response
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Initial increase in serum PSA
Number of subjects: 1006
Study: 16416385

Group type: EXPERIMENTAL
Intervention: Artemisinin alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Artemisinin-retinol combination
Number of subjects: 45
Study: 12574177

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 3684

Group type: EXPERIMENTAL
Intervention: Risedronate 2.5 mg/d
Number of subjects: 3684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3684
Study: 10651544

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal band ligation (EVL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy (EVS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Upper gastrointestinal endoscopy (Control)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Emergency sclerotherapy (EVS)
Number of subjects: 40
Study: 8912123

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg daily; n = 20)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily; n = 18)
Number of subjects: 38
Study: 1747049

Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 6181951

Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30842172

Group type: EXPERIMENTAL
Intervention: Single-dose RSB analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Repeated-dose RSB analgesia
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Continuous infusion RSB analgesia
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no RSB analgesia)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cancer patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Benign disease patients
Number of subjects: 56
Study: 28112814

Group type: EXPERIMENTAL
Intervention: Duct-to-mucosa pancreaticogastrostomy
Number of subjects: 80

Group type: COMPARATOR
Intervention: Handsewn closure
Number of subjects: 80
Study: 26416147

Group type: EXPERIMENTAL
Intervention: Early BCG vaccine
Number of subjects: 2343

Group type: COMPARATOR
Intervention: Late BCG (current practice)
Number of subjects: 2343
Study: 24628498

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg) after 2 weeks of open-label treatment
Number of subjects: 405

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg) titrated at Weeks 4 or 6
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg for 12 weeks)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Escitalopram (remission by Week 6 or 8)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Escitalopram (baseline MADRS below median)
Number of subjects: 405
Study: 21767239

Group type: EXPERIMENTAL
Intervention: HAART therapy for 6 months
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HAART therapy for 12 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 33
Study: 19649993

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow cell (BMC) transplantation, intracoronary injection mean 7 days after STEMI
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no BMC transplantation)
Number of subjects: 60
Study: 17454725

Group type: EXPERIMENTAL
Intervention: Educational information (n=79)
Number of subjects: 157

Group type: COMPARATOR
Intervention: No educational information (n=78)
Number of subjects: 157
Study: 15181616

Group type: EXPERIMENTAL
Intervention: tissue-transglutaminase (t-TG) stick
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: t-TG/antigliadin antibodies (AGA) stick
Number of subjects: 142

Group type: COMPARATOR
Intervention: ELISAs
Number of subjects: 142
Study: 12520747

Group type: EXPERIMENTAL
Intervention: Nedaplatin single drug (100 mg/m2, i.v., every 3 weeks)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nedaplatin + vindesine
Number of subjects: 138

Group type: COMPARATOR
Intervention: Cisplatin + vindesine
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nedaplatin
Number of subjects: 138
Study: 9579495

Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg bolus, followed by 125 microg/ml via PCA)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Epidural fentanyl (100 microg bolus, followed by 25 microg/ml via PCA)
Number of subjects: 47
Study: 7657965

Group type: EXPERIMENTAL
Intervention: Attapulgite (600 mg tablets)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2575766

Group type: EXPERIMENTAL
Intervention: suriclone (1.50‐2.25 mg/d)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: lorazepam (5.0‐7.5 mg/d)
Number of subjects: 64

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study: 865585

Group type: EXPERIMENTAL
Intervention: Conventional sunburn‐spectrum light in gradually increasing doses
Number of subjects: 18

Group type: COMPARATOR
Intervention: Long‐wave ultraviolet light (control group)
Number of subjects: 18
Study: 30043678

Group type: COMPARATOR
Intervention: Unloaded walking
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Wearing the combat uniform
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Carrying the combat uniform plus combat backpack
Number of subjects: 39
Study: 28472802

Group type: EXPERIMENTAL
Intervention: LCCP group (n = 50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CG1 (n = 33)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CG2 (n = 17)
Number of subjects: 100
Study: 26065565

Group type: EXPERIMENTAL
Intervention: Selective COX-2 inhibitor (celecoxib)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drug (indomethacin)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 22251427

Group type: EXPERIMENTAL
Intervention: Home Visits (HV)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Telephone Contacts (TC)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Reference Controls (RC)
Number of subjects: 325
Study: 21872857

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (10 mg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 18269305

Group type: EXPERIMENTAL
Intervention: IMPACT intervention (n = 279)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Usual primary care (n = 272)
Number of subjects: 551
Study: 16530338

Group type: EXPERIMENTAL
Intervention: Preoperative 5x5 Gy radiation with immediate surgery
Number of subjects: 316

Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy, 1.8 Gy per fraction plus boluses of 5‐fluorouracil and leucovorin) with delayed surgery
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 316

Group type: COMPARATOR
Intervention: Short‐course radiation
Number of subjects: 316
Study: 12859301

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 46
Study: 11022267

Group type: EXPERIMENTAL
Intervention: Rush Immunotherapy (RIT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional Immunotherapy (CIT)
Number of subjects: 18
Study: 9206085

Group type: EXPERIMENTAL
Intervention: Acupuncture at points Neiguan (PC6) and Zusanli (ST36)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Acupuncture at non‐acupoints
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 48
Study: 1350686

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.05 mg/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atracurium (0.25 mg/kg)
Number of subjects: 18
Study: 6548499

Group type: EXPERIMENTAL
Intervention: Lepromatous patients
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Non‐lepromatous patients
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control Group (disease-free normal people)
Number of subjects: 360
Study: 31964450

Group type: EXPERIMENTAL
Intervention: Pelleted diets
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Mash diets
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Pelleted diets with increasing ME levels
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Increasing ME levels
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Increasing inert material inclusion in diets
Number of subjects: 1152
Study: 31810342

Group type: EXPERIMENTAL
Intervention: Individual Nutrition Education (IE)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Group Education (GE)
Number of subjects: 170
Study: 30048574

Group type: EXPERIMENTAL
Intervention: ER-/PR- tumors (n=118)
Number of subjects: 693

Group type: COMPARATOR
Intervention: ER+/PR- subtype (n=77)
Number of subjects: 693

Group type: COMPARATOR
Intervention: No endocrine therapy for ER+ DCIS
Number of subjects: 693

Group type: COMPARATOR
Intervention: Lumpectomy alone
Number of subjects: 693
Study: 27555146

Group type: EXPERIMENTAL
Intervention: Remifentanil anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil anesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (remifentanil and sufentanil)
Number of subjects: 60
Study: 25439407

Group type: EXPERIMENTAL
Intervention: Propofol 0.6 mg/kg + Ketamine 0.8 mg/kg + Midazolam 0.06 mg/kg (three-drug group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Etomidate 0.3 mg/kg (single-drug group)
Number of subjects: 60
Study: 22299761

Group type: EXPERIMENTAL
Intervention: Lateral branch neurotomy using cooled radiofrequency
Number of subjects: 51

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 51
Study: 19176733

Group type: EXPERIMENTAL
Intervention: green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) with adequate protein (AP) diet (50-60 g protein/d)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) with high-protein (HP) diet (100-120 g protein/d)
Number of subjects: 80

Group type: COMPARATOR
Intervention: adequate protein (AP) diet (50-60 g protein/d) + placebo
Number of subjects: 80
Study: 17762661

Group type: EXPERIMENTAL
Intervention: Electrocardiographic repolarization measures (QT intervals, TPE intervals, T-wave morphology parameters)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Echocardiographically determined LVM
Number of subjects: 220
Study: 15506577

Group type: EXPERIMENTAL
Intervention: Electronic communication within a practice-based research network (PBRN)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Mailed survey instruments to a nationwide sample of family physicians
Number of subjects: 55
Study: 11207837

Group type: EXPERIMENTAL
Intervention: Ambulatory training of strength, functional performance, and balance 3 times per week for 3 months
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo group attending 3 times a week for 3 months
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Both groups received identical physiotherapeutic treatment 2 times a week, excluding strengthening and balance training
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 57
Study: 9920444

Group type: EXPERIMENTAL
Intervention: Low-fat diet (20% of total caloric intake as fat)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Usual diet (control group)
Number of subjects: 115
Study: 7999459

Group type: EXPERIMENTAL
Intervention: Estrogen-replacement therapy (ERT) with Premarin at 0.625 mg, days 1-25
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (study control)
Number of subjects: 0
Study: 3258994

Group type: EXPERIMENTAL
Intervention: Electrical Stimulation Group (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Voluntary Exercise Group (n = 10)
Number of subjects: 20
Study: 29249584

Group type: COMPARATOR
Intervention: UFT/LV (300-600 mg/d UFT with 75 mg/d LV on days 1-28, every 35 days, for 5 cycles)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: SOX (100 mg/m2 of oxaliplatin on day 1 with 80-120 mg/d S-1 on days 1-14, every 21 days, for 8 cycles)
Number of subjects: 966

Group type: EXPERIMENTAL
Intervention: SOX
Number of subjects: 966

Group type: COMPARATOR
Intervention: UFT/LV
Number of subjects: 966
Study: 28797414

Group type: EXPERIMENTAL
Intervention: Low transaortic flow rate (FR) defined as <200 ml/s
Number of subjects: 1661
Study: 25632079

Group type: EXPERIMENTAL
Intervention: a-tDCS over right M1 (n = 10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: s-tDCS (n = 10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: a-tDCS over right M1 without MVF (n = 8)
Number of subjects: 28
Study: 23921143

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Erythropoiesis-stimulating agent (ESA)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ESA and endurance training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 21385195

Group type: EXPERIMENTAL
Intervention: Mesalazine 4.8 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mesalazine 2.4 g/day
Number of subjects: 0
Study: 17853395

Group type: EXPERIMENTAL
Intervention: Gabapentin (target dose, 2700 mg) for 6 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 115
Study: 15460358

Group type: EXPERIMENTAL
Intervention: 16-min. guided imagery
Number of subjects: 42

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 42
Study: 11603905

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 9696975

Group type: EXPERIMENTAL
Intervention: One litre water and glycerine enema the day before operation (n = 53)
Number of subjects: 106

Group type: COMPARATOR
Intervention: No preoperative intestinal preparation (n = 53)
Number of subjects: 106
Study: 8014550

Group type: EXPERIMENTAL
Intervention: A1 pulley divided
Number of subjects: 100

Group type: COMPARATOR
Intervention: A1 pulley retained
Number of subjects: 100
Study: 2612087

Group type: EXPERIMENTAL
Intervention: Felodipine plus ethanol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Felodipine
Number of subjects: 10
Study: 1095964

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (150 mg daily) and vitamin B-12 (2000 gamma)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Vitamin B-12 (2000 gamma) alone
Number of subjects: 53
Study: 31838011

Group type: EXPERIMENTAL
Intervention: Olanzapine 5 mg
Number of subjects: 710

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 710
Study: 29730393

Group type: EXPERIMENTAL
Intervention: Virtual reality games (VIGOR) played for nine weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional graded activity or graded exposure therapies
Number of subjects: 0
Study: 27714429

Group type: EXPERIMENTAL
Intervention: 200 μg LSD
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 100 μg LSD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 26279073

Group type: EXPERIMENTAL
Intervention: 200 µg chromium picolinate supplements
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 24179293

Group type: EXPERIMENTAL
Intervention: Bright light (∼3000 lux, ∼7 Watts/m(2)) + melatonin (5 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Bright light (∼3000 lux, ∼7 Watts/m(2))
Number of subjects: 36

Group type: COMPARATOR
Intervention: Melatonin (5 mg)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Dim light (∼1.9 lux, ∼0.6 Watts/m(2)) + placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dim light (∼1.9 lux, ∼0.6 Watts/m(2)) + melatonin (5 mg)
Number of subjects: 36
Study: 20521076

Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of energy)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Low-fat diet (29% of energy)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Wash-in diet rich in saturated fatty acids
Number of subjects: 2
Study: 18805524

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (20 mg daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alendronate (70 mg weekly)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 60
Study: 16567432

Group type: EXPERIMENTAL
Intervention: Supine-elevated position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine-flat position
Number of subjects: 0
Study: 15034228

Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 68
Study: 11439832

Group type: EXPERIMENTAL
Intervention: Visited mothers (n = 108)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Nonvisited mothers (n = 104)
Number of subjects: 212
Study: 9886891

Group type: EXPERIMENTAL
Intervention: orlistat 120 mg three times a day (tid)
Number of subjects: 3132

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 3132
Study: 7987364

Group type: EXPERIMENTAL
Intervention: Midluteal phase (ML) at 35% intensity
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Midluteal phase (ML) at 60% intensity
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Midluteal phase (ML) at 75% intensity
Number of subjects: 9

Group type: COMPARATOR
Intervention: Midfollicular phase (MF) at 35% intensity
Number of subjects: 9

Group type: COMPARATOR
Intervention: Midfollicular phase (MF) at 60% intensity
Number of subjects: 9

Group type: COMPARATOR
Intervention: Midfollicular phase (MF) at 75% intensity
Number of subjects: 9
Study: 2736696

Group type: EXPERIMENTAL
Intervention: Li Dan Ling treatment group
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 1098726

Group type: EXPERIMENTAL
Intervention: Peroperative intermittent calf compression with low-dose heparin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Peroperative intermittent calf compression without low-dose heparin (control)
Number of subjects: 84
Study: 31302353

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training (RehaCom software, 16 sessions)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Pharmacological treatment alone
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cognitive training in schizophrenia patients
Number of subjects: 65
Study: 27050662

Group type: EXPERIMENTAL
Intervention: Nonlinear resistance training (NLRT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 21
Study: 24431394

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 23290018

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E ε4 allele presence
Number of subjects: 99

Group type: COMPARATOR
Intervention: Proinflammatory and prothrombotic polymorphisms
Number of subjects: 99
Study: 21799138

Group type: EXPERIMENTAL
Intervention: Dynamic balance exercises coupled with video game play
Number of subjects: 30

Group type: COMPARATOR
Intervention: Typical rehabilitation program consisting of strengthening and balance exercises
Number of subjects: 30
Study: 19825777

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery with functional after-treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Conservative treatment by functional bracing
Number of subjects: 83
Study: 16891328

Group type: EXPERIMENTAL
Intervention: Wide, long needle (23 gauge/0.6 mm diameter, 25 mm)
Number of subjects: 696

Group type: COMPARATOR
Intervention: Narrow, short needle (25 gauge/0.5 mm diameter, 16 mm)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Narrow, long needle (25 gauge, 25 mm)
Number of subjects: 696